Summary by Moomoo AI
New Sharp Pharmaceuticals International Holdings Limited (“New Sharp Pharmaceuticals”) will hold its Annual General Meeting on 18 June 2024 at the Global Building, 19 Des Voeux Road Central, Hong Kong. The agenda of the meeting includes the review and approval of the audited consolidated financial statements, the Board's reports and the auditor's report for the year ended 31 December 2023. In addition, the Board will re-elect directors, including Ms. Wang Qiu Qin, Mr. Xue Ping and Mr. Leung Chi Kin, and will authorize the Board to determine the directors' remuneration. The General Meeting will also renew the appointment of Dawa Maschuyun Accounting Firm as auditor for the next fiscal year and authorize the Board of Directors to determine his remuneration. Shareholders will vote on whether to authorize the Company to issue, distribute and dispose of shares under certain conditions and to repurchase shares not exceeding 10% of the issued shares. The eligibility of the shareholders to attend the general meeting will be determined on the basis of the share register on June 12, 2024.
